Curis, Inc. (CRIS) News
Filter CRIS News Items
CRIS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CRIS News Highlights
- CRIS's 30 day story count now stands at 5.
- Over the past 13 days, the trend for CRIS's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about CRIS are ASH and CNS.
Latest CRIS News From Around the Web
Below are the latest news stories about CURIS INC that investors may wish to consider to help them evaluate CRIS as an investment opportunity.
Curis, Inc. (NASDAQ:CRIS) Surges 54% Yet Its Low P/S Is No Reason For ExcitementCuris, Inc. ( NASDAQ:CRIS ) shareholders would be excited to see that the share price has had a great month, posting a... |
Curis Announces Initial Combination Study Data from its TakeAim Lymphoma StudyCuris, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced initial combination study data from its TakeAim Lymphoma trial including 5 primary CNS lymphoma (PCNSL) patients. |
Curis Presented Clinical Data from the TakeAim Leukemia Study at the 2023 ASH ConferenceCuris, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, last night presented clinical data from its TakeAim Leukemia Study at the 2023 ASH Conference. |
Curis Announces Three Presentations at ASHCuris, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company along with its collaborative partners will be presenting three posters at the upcoming 65th ASH Annual Meeting and Exposition (ASH 2025) being held in San Diego, California and online from December 9th to December 12th. |
Curis Enters into Agreement for Emavusertib / Pembrolizumab Combination Study in MelanomaCuris, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that it has entered into an investigator-initiated clinical trial agreement with the University of Florida to study the combination of emavusertib and pembrolizumab in patients with metastatic melanoma. |
Curis, Inc. (NASDAQ:CRIS) Q3 2023 Earnings Call TranscriptCuris, Inc. (NASDAQ:CRIS) Q3 2023 Earnings Call Transcript November 2, 2023 Curis, Inc. beats earnings expectations. Reported EPS is $-2.13, expectations were $-2.32. Operator: Good morning, and welcome to Curis’ Third Quarter 2023 Business Update Call. All participants will be in a listen-only mode. [Operator Instructions] After the company’s prepared remarks, all participants will have […] |
Curis Inc (CRIS) Reports Q3 2023 Financial Results: Net Loss Decreases Year-Over-YearCompany Continues Progress on Emavusertib Development, Maintains Strong Balance Sheet |
Curis Provides Third Quarter 2023 Business UpdateCuris, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 inhibitor for the treatment of hematologic malignancies, today reported its business update and financial results for the quarter ended September 30, 2023. |
2seventy bio, Inc. (TSVT) Expected to Beat Earnings Estimates: Should You Buy?2seventy bio, Inc. (TSVT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
Curis to Release Third Quarter 2023 Financial Results and Hold Conference Call on November 2, 2023Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 inhibitor for the treatment of hematologic malignancies, today announced that the Company will release its third quarter 2023 financial results on Thursday, November 2, 2023, at 8:00 a.m. ET. Management will host a conference call on the same day at 8:30 a.m. ET. |